Member Type: Diagnostic Companies
Biodesix is a personalized medicine company focused on the development of diagnostic products that inform treatment decisions and improve patient care. In 2009, Biodesix launched VeriStrat®, a serum-based proteomic test to help physicians guide treatment for patients with non-small cell lung cancer. VeriStrat is based on ProTS®, proprietary technology which harnesses the power of mass spectrometry and enables the discovery of specific molecular profiles that characterize a patient’s condition or likely outcome in response to therapy. The ProTS® platform has broad application and provides the foundation for collaborations with leading researchers as well as partnerships with biotechnology and pharmaceutical companies seeking to develop companion diagnostics and improve the targeting of their therapies.